Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Bladder Cancer, December 2023

Free Subscription


Abstracts

Retrieve all available abstracts of the following 258 articles:
HTML format


 

Single Articles

  1. WANG J, Wang T, Feng YK, Liu Y, et al
    Deubiquitinating enzyme PSMD7 promotes bladder cancer development: Involvement of RAB1A stabilization.
    Cell Signal. 2023 Nov 29:110996. doi: 10.1016/j.cellsig.2023.110996.
    PubMed    
    Abstract available

  2. CHEN H, Qi Y, Yang C, Tai Q, et al
    Heterogeneous MXene Hybrid-Oriented Exosome Isolation and Metabolic Profiling for Early Screening, Subtyping and Follow-up Evaluation of Bladder Cancer.
    ACS Nano. 2023 Dec 1. doi: 10.1021/acsnano.3c08391.
    PubMed    
    Abstract available

  3. LU G, Qiu Y
    SPI1-mediated CXCL12 expression in bladder cancer affects the recruitment of tumor-associated macrophages.
    Mol Carcinog. 2023 Dec 1. doi: 10.1002/mc.23663.
    PubMed    
    Abstract available

  4. HANNOUNEH ZA, Hijazi A, Alsaleem AA, Hami S, et al
    Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.
    Cancer Med. 2023 Dec 1. doi: 10.1002/cam4.6768.
    PubMed    
    Abstract available

  5. LUO KW, Chen W, Lung WY, Wei XY, et al
    Corrigendum to "EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down-regulation of NF-kappaB and MMP-9" [Journal of Nutritional Biochemistry 41 (2017) 56-64].
    J Nutr Biochem. 2023 Nov 29:109530. doi: 10.1016/j.jnutbio.2023.109530.
    PubMed    


  6. SYNELNYK T, Vovk T, Halenova T, Tytarenko V, et al
    Evaluation of proteolytic activity and serine proteases distribution in plasma from patients with bladder cancer.
    Front Med (Lausanne). 2023;10:1276882.
    PubMed    
    Abstract available

  7. MAVRIDIS C, Venihaki M, Dermitzaki E, Deiktakis M, et al
    mRNA expression of CRF family members in urothelial bladder cancer.
    Oncol Lett. 2023;27:13.
    PubMed    
    Abstract available

  8. DONG Y, Cheng Y, Guo H, Sun J, et al
    Association of obesity and different metabolic status with prognosis in patients with bladder cancer: a retrospective cohort study.
    Ther Adv Urol. 2023;15:17562872231213720.
    PubMed    
    Abstract available

  9. RANGEL MMM, Linhares LCM, de Oliveira KD, Suzuki DOH, et al
    Evaluation of the safety and feasibility of electrochemotherapy with intravenous bleomycin as local treatment of bladder cancer in dogs.
    Sci Rep. 2023;13:21078.
    PubMed    
    Abstract available

  10. LIAO J, Zhou Z
    Long-term cardiovascular mortality risk in patients with bladder cancer: a real-world retrospective study of 129,765 cases based on the SEER database.
    Front Cardiovasc Med. 2023;10:1142417.
    PubMed    
    Abstract available


  11. LINC-PINT Inhibited Malignant Progression of Bladder Cancer by Targeting miR-155-5p [Retraction].
    Cancer Manag Res. 2023;15:1267-1268.
    PubMed    
    Abstract available

  12. KOURIE HR, Zouein J, Succar B, Mardirossian A, et al
    Genetic Polymorphisms Involved in Bladder Cancer: A Global Review.
    Oncol Rev. 2023;17:10603.
    PubMed    
    Abstract available

  13. HODARA E, Mades A, Swartz L, Iqbal M, et al
    m(6)A epitranscriptome analysis reveals differentially methylated transcripts that drive early chemoresistance in bladder cancer.
    NAR Cancer. 2023;5:zcad054.
    PubMed    
    Abstract available

  14. CHORBINSKA J, Krajewski W, Nowak L, Bardowska K, et al
    Is the Urinary and Gut Microbiome Associated With Bladder Cancer?
    Clin Med Insights Oncol. 2023;17:11795549231206796.
    PubMed    
    Abstract available

  15. TAMADA S, Ikarashi D, Yanagawa N, Toyoshima M, et al
    Metastatic bladder cancer forming a sigmoidorectal fistula after enfortumab vedotin therapy: a case report.
    Front Oncol. 2023;13:1274494.
    PubMed    
    Abstract available

  16. WANG Y, Wang J, He J, Ji B, et al
    Comprehensive analysis of PRPF19 immune infiltrates, DNA methylation, senescence-associated secretory phenotype and ceRNA network in bladder cancer.
    Front Immunol. 2023;14:1289198.
    PubMed    
    Abstract available

  17. MA YT, Hua F, Zhong XM, Xue YJ, et al
    Clinicopathological characteristics, molecular landscape, and biomarker landscape for predicting the efficacy of PD-1/PD-L1 inhibitors in Chinese population with mismatch repair deficient urothelial carcinoma: a real-world study.
    Front Immunol. 2023;14:1269097.
    PubMed    
    Abstract available

  18. DONG L, Lin F, Wu W, Huang W, et al
    Erratum: Transcriptional cofactor Mask2 is required for YAP-induced cell growth and migration in bladder cancer cell: Erratum.
    J Cancer. 2023;14:3521-3522.
    PubMed    
    Abstract available

  19. HESSWANI C, Jackson CL, Marcq G, Hardy C, et al
    Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy.
    Eur Urol Open Sci. 2023;57:22-29.
    PubMed    
    Abstract available

  20. BOHNER P, Pal M, Crettenand F, Roth B, et al
    [Bladder cancer : a comprehensive follow-up for an efficient and personalized care].
    Rev Med Suisse. 2023;19:2250-2253.
    PubMed    
    Abstract available

  21. REALE S, Bohner P, Crettenand F, Roth B, et al
    [Radical cystectomy in the geriatric population. Tools for screening postoperative complications].
    Rev Med Suisse. 2023;19:2247-2249.
    PubMed    
    Abstract available

  22. CHEN H, Shi D, Guo C, Zhang W, et al
    Can uric acid affect the immune microenvironment in bladder cancer? A single-center multi-omics study.
    Mol Carcinog. 2023 Nov 29. doi: 10.1002/mc.23664.
    PubMed    
    Abstract available

  23. LIU Z, Sun L, Zheng B, Wang H, et al
    The value of ATAD3A as a potential biomarker for bladder cancer.
    Cancer Med. 2023 Nov 28. doi: 10.1002/cam4.6759.
    PubMed    
    Abstract available

  24. ZHOU G, Li Y, Ren X, Qin G, et al
    Identifying prognostic characteristics of m6A-related glycolysis gene and predicting the immune infiltration landscape in bladder cancer.
    Cancer Cell Int. 2023;23:300.
    PubMed    
    Abstract available

  25. MYOEN S, Mochizuki M, Shibuya-Takahashi R, Fujimori H, et al
    CD271 promotes proliferation and migration in bladder cancer.
    Genes Cells. 2023 Nov 28. doi: 10.1111/gtc.13087.
    PubMed    
    Abstract available

  26. JIN H, Liu B, Guo X, Qiao X, et al
    MYLK and CALD1 as molecular targets in bladder cancer.
    Medicine (Baltimore). 2023;102:e36302.
    PubMed    
    Abstract available

  27. LI J, Zhuang C, Liu Y, Chen M, et al
    Correction: Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer.
    J Exp Clin Cancer Res. 2023;42:321.
    PubMed    


  28. WANG L, Deng JY, Li KP, Shan-Yin, et al
    Inflammatory bowel disease and bladder cancer risk: based on a Mendelian randomization study.
    BMC Urol. 2023;23:195.
    PubMed    
    Abstract available

  29. YUE R, Dutta A
    Reparameterized multiobjective control of BCG immunotherapy.
    Sci Rep. 2023;13:20850.
    PubMed    
    Abstract available

  30. GUO C, Li P, Guo X, Wang X, et al
    Identification of bladder cancer subtypes and predictive model for prognosis, immune features, and immunotherapy based on neutrophil extracellular trap-related genes.
    Sci Rep. 2023;13:20791.
    PubMed    
    Abstract available

  31. KOBAYASHI Y, Iijima K, Kondo Y, Yamamoto K, et al
    Chronic polyradiculoneuropathy associated with pembrolizumab for bladder cancer.
    Acta Neurol Belg. 2023 Nov 27. doi: 10.1007/s13760-023-02439.
    PubMed    


  32. KISHI S, Mori S, Fujiwara-Tani R, Ogata R, et al
    ERVK13-1/miR-873-5p/GNMT Axis Promotes Metastatic Potential in Human Bladder Cancer though Sarcosine Production.
    Int J Mol Sci. 2023;24:16367.
    PubMed    
    Abstract available

  33. SAMARA M, Vlachostergios PJ, Thodou E, Zachos I, et al
    Characterization of a miRNA Signature with Enhanced Diagnostic and Prognostic Power for Patients with Bladder Carcinoma.
    Int J Mol Sci. 2023;24:16243.
    PubMed    
    Abstract available

  34. FAHEY CC, Nebhan CA, York S, Davis NB, et al
    Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin.
    Int J Mol Sci. 2023;24:16109.
    PubMed    
    Abstract available

  35. BERNDT-PAETZ M, Han S, Weimann A, Reinhold A, et al
    Cell Line-Based Human Bladder Organoids with Bladder-like Self-Organization-A New Standardized Approach in Bladder Cancer Research.
    Biomedicines. 2023;11:2958.
    PubMed    
    Abstract available

  36. AKIN O, Lema-Dopico A, Paudyal R, Konar AS, et al
    Multiparametric MRI in Era of Artificial Intelligence for Bladder Cancer Therapies.
    Cancers (Basel). 2023;15:5468.
    PubMed    
    Abstract available

  37. ZHANG Z, Yu Y, Zhang Z, Li D, et al
    Cancer-associated fibroblasts-derived CXCL12 enhances immune escape of bladder cancer through inhibiting P62-mediated autophagic degradation of PDL1.
    J Exp Clin Cancer Res. 2023;42:316.
    PubMed    
    Abstract available

  38. KHEDR OS, Wahed ME, Al-Attar AR, Abdel-Rehim EA, et al
    The classification of the bladder cancer based on Vision Transformers (ViT).
    Sci Rep. 2023;13:20639.
    PubMed    
    Abstract available

  39. FUJIWARA M, Tanaka H, Kobayashi M, Nakamura Y, et al
    Neoadjuvant Chemoradiotherapy Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer: Analysis of Efficacy and Safety in 119 Patients.
    Clin Genitourin Cancer. 2023 Nov 2:S1558-7673(23)00232.
    PubMed    
    Abstract available

  40. KNAPP DW, Dhawan D, Ruple A, Cooper BR, et al
    Association between cigarette smoke exposure and urinary bladder cancer in Scottish terriers in a cohort study.
    Vet J. 2023 Nov 22:106044. doi: 10.1016/j.tvjl.2023.106044.
    PubMed    
    Abstract available

  41. LIU L, Xiao Y, Wei D, Wang Q, et al
    Development and validation of a nomogram for predicting suicide risk and prognostic factors in bladder cancer patients following diagnosis: A population-based retrospective study.
    J Affect Disord. 2023;347:124-133.
    PubMed    
    Abstract available

  42. YU J, Lee CU, Chung JH, Song W, et al
    Impact of urinary diversion type on urethral recurrence following radical cystectomy for bladder cancer: Propensity score matched and weighted analyses of retrospective cohort.
    Int J Surg. 2023 Nov 23. doi: 10.1097/JS9.0000000000000904.
    PubMed    
    Abstract available

  43. TSILI AC
    VI-RADS scoring system for predicting 1- to 5-year recurrence of bladder cancer.
    Eur Radiol. 2023 Nov 24. doi: 10.1007/s00330-023-10458.
    PubMed    


  44. TEMPO J, Bolton D, O'Callaghan M
    Seminal papers in urology: maintenance Bacillus Calmette-Guerin (BCG) immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study (SWOG-8507).
    BMC Urol. 2023;23:194.
    PubMed    
    Abstract available

  45. MEDORI MC, Micheletti C, Madeo G, Maltese PE, et al
    Omics sciences and precision medicine in Urothelial Carcinoma.
    Clin Ter. 2023;174.
    PubMed    
    Abstract available

  46. TANG X, Zhan X, Chen X
    Incidence, mortality and survival of transitional cell carcinoma in the urinary system: A population-based analysis.
    Medicine (Baltimore). 2023;102:e36063.
    PubMed    
    Abstract available


  47. [Not Available].
    Aktuelle Urol. 2023;54:434.
    PubMed    


  48. SCHALLENBERG S, Plage H, Hofbauer S, Furlano K, et al
    Altered p53/p16 expression is linked to urothelial carcinoma progression but largely unrelated to prognosis in muscle-invasive tumors.
    Acta Oncol. 2023;62:1880-1889.
    PubMed    
    Abstract available

  49. DHALL A, Patiyal S, Kaur H, Raghava GPS, et al
    Risk assessment of cancer patients based on HLA-I alleles, neobinders and expression of cytokines.
    Comput Biol Med. 2023;167:107594.
    PubMed    
    Abstract available

  50. STONE L
    Bladder-sparing neoadjuvant therapy for MIBC.
    Nat Rev Urol. 2023;20:703.
    PubMed    


  51. SANO T, Saito R, Aizawa R, Watanabe T, et al
    Current trends in the promising immune checkpoint inhibition and radiotherapy combination for locally advanced and metastatic urothelial carcinoma.
    Int J Clin Oncol. 2023;28:1573-1584.
    PubMed    
    Abstract available

  52. MARJERRISON N, Grimsrud TK, Hansen J, Martinsen JI, et al
    Occupational exposures of firefighting and urinary tract cancer risk among men in the Norwegian Fire Departments Cohort.
    Occup Environ Med. 2023;80:659-666.
    PubMed    
    Abstract available

  53. TOYODA T, Kobayashi T, Miyoshi N, Matsushita K, et al
    Mucosal damage and gamma-H2AX formation in the rat urinary bladder induced by aromatic amines with structures similar to o-toluidine and o-anisidine.
    Arch Toxicol. 2023;97:3197-3207.
    PubMed    
    Abstract available

  54. LIAO PJ, Lee CH, Wang SL, Chiou HY, et al
    Low-to-Moderate Arsenic Exposure and Urothelial Tract Cancers with a Long Latent Period of Follow-Up in an Arseniasis Area.
    J Epidemiol Glob Health. 2023;13:807-815.
    PubMed    
    Abstract available

  55. SAVIN Z, Yossepowitch O, Lazarovich A, Rosenzwieg B, et al
    11-item modified frailty index and outcomes after radical cystectomy.
    J Geriatr Oncol. 2023;14:101627.
    PubMed    
    Abstract available

  56. ANDRUSKA N, Waters MR, Fischer-Valuck BW, Smith ZL, et al
    Does Chemo-Radiotherapy Improve Survival Outcomes vs. Radiotherapy Alone for High-Grade cT1 Urothelial Carcinoma of the Bladder?
    Clin Genitourin Cancer. 2023;21:653-659.
    PubMed    
    Abstract available

  57. ROSENBERG JE, Powles T, Sonpavde GP, Loriot Y, et al
    EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
    Ann Oncol. 2023;34:1047-1054.
    PubMed    
    Abstract available

  58. BASCIO LS, Chiappa V, Paolini B, Chiarello G, et al
    Urothelial bladder carcinoma recurrence in the uterine cervix: Cytological findings on a cervical cytology test.
    Cytopathology. 2023;34:645-648.
    PubMed    


  59. KIR G, Cecikoglu GE, Topal CS, Sorkun MH, et al
    Clinicopathologic features and prognostic significance of mixed (Low and high-grade) papillary urothelial carcinoma comparison with low and high-grade papillary urothelial carcinoma.
    Virchows Arch. 2023;483:621-634.
    PubMed    
    Abstract available

  60. NOGRADI AL, Cope I, Arany-Toth A, Muller L, et al
    Primary Urinary Bladder Tumors in Three Guinea Pigs (Cavia Porcellus).
    Top Companion Anim Med. 2023;56-57:100805.
    PubMed    
    Abstract available

  61. AHN H, Kim TM, Hwang SI, Lee HJ, et al
    Tumor contact length with bladder wall provides effective risk stratification for lesions with a VIRADS score of 2-3.
    Eur Radiol. 2023;33:8417-8425.
    PubMed    
    Abstract available

  62. KLOSE C, Gordon O, Sparks A, Whalen M, et al
    Trends of Lymph Node Outcomes in Partial Cystectomy for Muscle-Invasive Urothelial Carcinoma of the Bladder.
    Clin Genitourin Cancer. 2023;21:703-709.
    PubMed    
    Abstract available

  63. AGRAWAL P, Rostom M, Alam R, Florissi I, et al
    Clinicopathologic and Survival After Cystectomy Outcomes in Squamous Cell Carcinoma of the Bladder.
    Clin Genitourin Cancer. 2023;21:631-638.
    PubMed    
    Abstract available

  64. ACAR O, Ayhan M, Demir B, Ekinci F, et al
    HALP Score as a New Prognostic Factor for Patients with Metastatic Bladder Cancer.
    J Coll Physicians Surg Pak. 2023;33:1405-1409.
    PubMed    
    Abstract available

  65. LIU T, Xu X, Li J, Bai M, et al
    ALOX5 deficiency contributes to bladder cancer progression by mediating ferroptosis escape.
    Cell Death Dis. 2023;14:800.
    PubMed    
    Abstract available

  66. NOEL ODV, Hassouneh Z, Svatek RS, Mukherjee N, et al
    Innate Lymphoid Cells in Bladder Cancer: From Mechanisms of Action to Immune Therapies.
    Cancer Immunol Res. 2023 Dec 7:OF1-OF12. doi: 10.1158/2326-6066.CIR-23-0414.
    PubMed    
    Abstract available

  67. WANG Z, Ying Y, Wang M, Chen Q, et al
    Comprehensive identification of onco-exaptation events in bladder cancer cell lines revealed L1PA2-SYT1 as a prognosis-relevant event.
    iScience. 2023;26:108482.
    PubMed    
    Abstract available

  68. YANG J, Jiang X, Chen Y, Teng L, et al
    EIF5A2 Promotes Doxorubicin Resistance in Bladder Cancer Cells through the TGF-beta Signaling Pathway.
    Discov Med. 2023;35:1167-1176.
    PubMed    
    Abstract available

  69. AN WX, Gupta R, Zhai K, Wang YR, et al
    Current and Potential Roles of Ferroptosis in Bladder Cancer.
    Curr Med Sci. 2023 Dec 7. doi: 10.1007/s11596-023-2814.
    PubMed    
    Abstract available

  70. ZHUANG J, Cai L, Sun H, Wu Q, et al
    Vesical imaging reporting and data system (VI-RADS) could predict the survival of bladder-cancer patients who received radical cystectomy.
    Sci Rep. 2023;13:21502.
    PubMed    
    Abstract available

  71. LI W, Shen Y, Yang C, Ye F, et al
    Identification of a novel ferroptosis-inducing micropeptide in bladder cancer.
    Cancer Lett. 2023 Dec 4:216515. doi: 10.1016/j.canlet.2023.216515.
    PubMed    
    Abstract available

  72. TENG C, Liu Z, Wang J, Shi S, et al
    C15:0 and C17:0 partially mediate the association of milk &dairy products with bladder cancer risk.
    J Dairy Sci. 2023 Dec 4:S0022-0302(23)00830-5. doi: 10.3168/jds.2023-24186.
    PubMed    
    Abstract available

  73. HOOGEVEEN F, Blanker MH, Cauberg E, Steffens MG, et al
    Recurrence of non-muscle invasive bladder carcinoma after transurethral resection with hexaminolevulinate photodynamic diagnosis or regular cystoscopy.
    Scand J Urol. 2023;58:120-125.
    PubMed    
    Abstract available

  74. ZHENG J, Peng L, Zhang S, Liao H, et al
    Preoperative systemic immune-inflammation index as a prognostic indicator for patients with urothelial carcinoma.
    Front Immunol. 2023;14:1275033.
    PubMed    
    Abstract available

  75. EBNER B, Fleckenstein F, Volz Y, Eismann L, et al
    Oncological impact of perioperative blood transfusion in bladder cancer patients undergoing radical cystectomy: Do we need to consider storage time of blood units, donor age, or gender matching?
    Transfusion. 2023 Dec 6. doi: 10.1111/trf.17618.
    PubMed    
    Abstract available

  76. DONG X, Wang Y, Wang S, Li C, et al
    Clinical Effect of the Combination of Compound Kushen Injection and Gemcitabine on Postoperative Patients with Non-Muscle Invasive Bladder Cancer and Its Influence on Serum-Related Factors.
    Arch Esp Urol. 2023;76:657-665.
    PubMed    
    Abstract available

  77. HAN Y, Kim U, Jung KJ, Lee JY, et al
    Metabolic changes preceding bladder cancer occurrence among Korean men: a nested case-control study from the KCPS-II cohort.
    Cancer Metab. 2023;11:23.
    PubMed    
    Abstract available

  78. WU JM, Qiu WR, Liu Z, Xu ZC, et al
    Integrative approach for classifying male tumors based on DNA methylation 450K data.
    Math Biosci Eng. 2023;20:19133-19151.
    PubMed    
    Abstract available

  79. JIANG YK, Shuai YJ, Ding HM, Zhang H, et al
    Erratum to: ARID1A Inactivation Increases Expression of circ0008399 and Pro-motes Cisplatin Resistance in Bladder Cancer.
    Curr Med Sci. 2023 Dec 4. doi: 10.1007/s11596-023-2819.
    PubMed    


  80. LI H, Lin G, Cui M, Wang L, et al
    Hub biomarkers in ultrasound-guided bladder cancer and osteosarcoma: Myosin light chain kinase and caldesmon.
    Medicine (Baltimore). 2023;102:e36414.
    PubMed    
    Abstract available

  81. ZHU S, Zhao Q, Fan Y, Tang C, et al
    Development of a prognostic model to predict BLCA based on anoikis-related gene signature: preliminary findings.
    BMC Urol. 2023;23:199.
    PubMed    
    Abstract available

  82. CHI BJ, Duan ZL, Hasan AHAM, Yin XZ, et al
    Effect and Mechanism of Curdione Combined with Gemcitabine on Migration and Invasion of Bladder Cancer.
    Biochem Genet. 2023 Dec 5. doi: 10.1007/s10528-023-10584.
    PubMed    
    Abstract available

  83. MAITRE P, Choudhury A
    Bladder Preservation and Immunotherapy: Rebel Without A Cause?
    Int J Radiat Oncol Biol Phys. 2024;118:50-51.
    PubMed    


  84. LIVERINGHOUSE C, Netzley A, Bryant JM, Linkowski LC, et al
    Trimodal Therapy Using an MR-guided Radiation Therapy Partial Bladder Tumor Boost in Muscle Invasive Bladder Cancer.
    Adv Radiat Oncol. 2023;8:101268.
    PubMed    
    Abstract available

  85. SINGH P, Parida GK, Bishnoi K, Singhal T, et al
    Delayed Recurrence of Gall Bladder Cancer as Port-site Metastases with Occult Primary Detected on Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography: A Tale of Two Cases.
    Indian J Nucl Med. 2023;38:273-275.
    PubMed    
    Abstract available

  86. SOLOWAY MS
    Inflection points in urology as witnessed by Mark Soloway. Part 1: bladder cancer.
    Cent European J Urol. 2023;76:263-268.
    PubMed    


  87. WIELAND VLS, Uysal D, Probst P, Grilli M, et al
    Framework for a living systematic review and meta-analysis for the surgical treatment of bladder cancer: introducing EVIglance to urology.
    Int J Surg Protoc. 2023;27:9-15.
    PubMed    
    Abstract available

  88. FURUYA H, Sakatani T, Tanaka S, Murakami K, et al
    Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms.
    Res Sq. 2023 Nov 25:rs.3.rs-3635581. doi: 10.21203/rs.3.rs-3635581.
    PubMed    
    Abstract available

  89. CAI X, Ruan L, Wang D, Zhang J, et al
    Boosting chemotherapy of bladder cancer cells by ferroptosis using intelligent magnetic targeting nanoparticles.
    Colloids Surf B Biointerfaces. 2023;234:113664.
    PubMed    
    Abstract available

  90. LIU Y, Ye F, Yang C, Jiang H, et al
    Use of in vivo Raman spectroscopy and cryoablation for diagnosis and treatment of bladder cancer.
    Spectrochim Acta A Mol Biomol Spectrosc. 2023;308:123707.
    PubMed    
    Abstract available

  91. KIM JM, Choi E, Sung SH, Jo J, et al
    Does Bladder Cancer Subtype Influence Pathologic Complete Response (pCR) and Pelvic Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Response Evaluation After Neoadjuvant Chemotherapy? Pathological Perspective.
    Clin Genitourin Cancer. 2023 Nov 10:S1558-7673(23)00240.
    PubMed    
    Abstract available

  92. FRANCOLINI G, Ghoshal A, Caini S, Piazzini T, et al
    Quality of life after definitive treatment for bladder cancer: A systematic review and meta-analysis.
    Radiother Oncol. 2023;190:110038.
    PubMed    
    Abstract available

  93. MA C, Zhong X, Liu R, Yang X, et al
    Co-delivery of oxaliplatin prodrug liposomes with Bacillus Calmette-Guerin for chemo-immunotherapy of orthotopic bladder cancer.
    J Control Release. 2023;365:640-653.
    PubMed    
    Abstract available

  94. JOBST M, Hossain M, Kiss E, Bergen J, et al
    Autophagy modulation changes mechano-chemical sensitivity of T24 bladder cancer cells.
    Biomed Pharmacother. 2023;170:115942.
    PubMed    
    Abstract available

  95. QIU Y, Ye W, Wang C, Zang J, et al
    Prognostic significance and immunoinfiltration analysis of genes associated with epithelial-mesenchymal transition and energy metabolism in bladder urothelial carcinoma.
    Aging (Albany NY). 2023;15:13312-13328.
    PubMed    
    Abstract available

  96. CHEN J, Chen S, Luo H, Wan X, et al
    The complementary and alternative roles of elemene injection in cancer: An umbrella review.
    Pharmacol Res. 2023;198:107007.
    PubMed    
    Abstract available

  97. FIGAROA OJA, Hendriks N, Kamphuis GM, van Moorselaar RJA, et al
    Positioning the role of urine cytology within the diagnostic pathway for UTUC: supportive but inconclusive.
    World J Urol. 2023;41:3429-3435.
    PubMed    
    Abstract available

  98. TSUJINO T, Komura K, Inamoto T, Maenosono R, et al
    Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinoma.
    World J Urol. 2023;41:3585-3591.
    PubMed    
    Abstract available

  99. CHEN JC, Huang TH, Wei TC, Huang IS, et al
    Influence of preoperative body mass index on prognosis for patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy.
    World J Urol. 2023;41:3575-3583.
    PubMed    
    Abstract available

  100. KOELKER M, Bradtke M, Klemm J, von Deimling M, et al
    Rational peri-operative management of antithrombotic therapy in patients undergoing radical cystectomy: A 30-day morbidity analysis based on the updated European Association of Urology guidelines for standardized complication reporting.
    Eur J Surg Oncol. 2023;49:107123.
    PubMed    
    Abstract available

  101. RICH JM, Geduldig J, Cumarasamy S, Ranti D, et al
    Eliminating the routine use of postoperative drain placement in patients undergoing robotic-assisted radical cystectomy with intracorporeal urinary diversion.
    Urol Oncol. 2023;41:457.
    PubMed    
    Abstract available

  102. WANG B, Ou Z, Zhong W, Huang L, et al
    Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant.
    Cancer Immunol Res. 2023;11:1656-1670.
    PubMed    
    Abstract available

  103. ALHALABI O, Wilson N, Xiao L, Lin Y, et al
    Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract.
    Eur Urol Oncol. 2023;6:611-620.
    PubMed    
    Abstract available

  104. GRAHN A, Coleman JA, Eriksson Y, Gabrielsson S, et al
    Consultation on UTUC II Stockholm 2022: diagnostic and prognostic methods-what's around the corner?
    World J Urol. 2023;41:3405-3411.
    PubMed    
    Abstract available

  105. MU N, Jylha C, Axelsson T, Syden F, et al
    Patient-specific targeted analysis of circulating tumour DNA in plasma is feasible and may be a potential biomarker in UTUC.
    World J Urol. 2023;41:3421-3427.
    PubMed    
    Abstract available

  106. CALLERIS G, Roupret M, Seisen T, Bendjeddou L, et al
    Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756).
    World J Urol. 2023;41:3413-3420.
    PubMed    
    Abstract available

  107. YIM K, Melnick K, Mott SL, Carvalho FLF, et al
    Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy.
    Urol Oncol. 2023;41:458.
    PubMed    
    Abstract available

  108. SYDEN F, Baard J, Bultitude M, Keeley FX Jr, et al
    Consultation on UTUC II Stockholm 2022: diagnostics, prognostication, and follow-up-where are we today?
    World J Urol. 2023;41:3395-3403.
    PubMed    
    Abstract available

  109. BLACHMAN-BRAUN R, Gurayah AA, Mason MM, Hougen HY, et al
    Incidence and predictors of deep incisional and organ/space surgical site infection following radical cystectomy.
    Urol Oncol. 2023;41:455.
    PubMed    
    Abstract available

  110. NYAME YA, Baker KK, Montgomery B, Grivas P, et al
    Racial and sex differences in tumor genomics in urothelial carcinoma.
    Urol Oncol. 2023;41:456.
    PubMed    
    Abstract available

  111. KAZAN O, Gunduz N, Bakir B, Iplikci A, et al
    Diagnostic validity of the vesical imaging-reporting and data system (VI-RADS): a real-world study.
    Actas Urol Esp (Engl Ed). 2023;47:638-644.
    PubMed    
    Abstract available

  112. ROSE KM, Murray KS, Labbate C, Woldu S, et al
    Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease.
    Eur Urol Focus. 2023;9:807-812.
    PubMed    
    Abstract available

  113. RYAN PC, Kelly C, Afridi I, Fawaz A, et al
    Surgical treatment of urachal remnants in an adult population-a single-centre experience.
    Ir J Med Sci. 2023;192:3023-3027.
    PubMed    
    Abstract available

  114. MARTINI A, Touzani A, Ploussard G
    Lower Detrusor Apron-sparing Robot-assisted Radical Cystectomy and Intracorporeal Neobladder Reconstruction: Technique and Preliminary Outcomes.
    Eur Urol Focus. 2023;9:760-764.
    PubMed    
    Abstract available

  115. ZHANG X, Wen Z, Xing Z, Zhou X, et al
    The causal relationship between osteoarthritis and bladder cancer: A Mendelian randomization study.
    Cancer Med. 2023 Dec 15. doi: 10.1002/cam4.6829.
    PubMed    
    Abstract available

  116. BAZARKIN A, Morozov A, Androsov A, Fajkovic H, et al
    Assessment of Prostate and Bladder Cancer Genomic Biomarkers Using Artificial Intelligence: a Systematic Review.
    Curr Urol Rep. 2023 Dec 15. doi: 10.1007/s11934-023-01193.
    PubMed    
    Abstract available

  117. CARRASCO R, Ingelmo-Torres M, Oriola J, Roldan FL, et al
    Assessment of aggressive bladder cancer mutations in plasma cell-free DNA.
    Front Oncol. 2023;13:1270962.
    PubMed    
    Abstract available

  118. TIAN X, Liu D, He P, Li L, et al
    DOK7, a target of miR-299-5p, suppresses the progression of bladder cancer.
    Aging (Albany NY). 2023;15.
    PubMed    
    Abstract available

  119. KHAN AR, Awan NUH, Tchier F, Alahmari SD, et al
    An estimation of physiochemical properties of bladder cancer drugs via degree-based chemical bonding topological descriptors.
    J Biomol Struct Dyn. 2023 Dec 14:1-9. doi: 10.1080/07391102.2023.2292792.
    PubMed    
    Abstract available

  120. ZHOU Y, Xu W, Zeng Y, Li H, et al
    Global research trends of the application of artificial intelligence in bladder cancer since the 21st century: a bibliometric analysis.
    Front Oncol. 2023;13:1227152.
    PubMed    
    Abstract available

  121. METHODS IN MEDICINE CAM
    Retracted: CASC1 Expression in Bladder Cancer Is Regulated by Exosomal miRNA-150: A Comprehensive Pan-Cancer and Bioinformatics Study.
    Comput Math Methods Med. 2023;2023:9867274.
    PubMed    
    Abstract available

  122. WANG H, Zhang M, Miao J, Hou F, et al
    Deep learning signature based on multiphase enhanced CT for bladder cancer recurrence prediction: a multi-center study.
    EClinicalMedicine. 2023;66:102352.
    PubMed    
    Abstract available

  123. WANG H, Lv Z, Xia H, Tang R, et al
    Cuproptosis-related long noncoding RNAs predicts overall survival and reveal immune microenvironment of bladder cancer.
    Heliyon. 2023;9:e21153.
    PubMed    
    Abstract available

  124. MICHAUD E, Mansure JJ, Kassouf W
    INTEGRATING NOVEL IMMUNOTHERAPEUTIC APPROACHES IN ORGAN-PRESERVING THERAPIES FOR BLADDER CANCER.
    Br J Pharmacol. 2023 Dec 13. doi: 10.1111/bph.16300.
    PubMed    
    Abstract available

  125. REN Y, Wang G, Wang P, Liu K, et al
    MM-SFENet: multi-scale multi-task localization and classification of bladder cancer in MRI with spatial feature encoder network.
    Phys Med Biol. 2023 Dec 13. doi: 10.1088/1361-6560/ad1548.
    PubMed    
    Abstract available

  126. WANG S, Ji Y, Liu Y, Du P, et al
    The values of HER-2 expression in the non-muscle-invasive bladder cancer: a retrospective clinical study.
    Front Oncol. 2023;13:1243118.
    PubMed    
    Abstract available

  127. WANG L, Wang W
    Symptom management and nursing interventions for postoperative bladder instillation chemotherapy in bladder cancer patients.
    Minerva Surg. 2023 Dec 13. doi: 10.23736/S2724-5691.23.10162.
    PubMed    


  128. GORE JL, Follmer K, Reynolds J, Nash M, et al
    Interruptions in bladder cancer care during the COVID-19 public health emergency.
    Urol Oncol. 2023 Dec 11:S1078-1439(23)00362.
    PubMed    
    Abstract available

  129. YU X, Li W, Sun S, Li J, et al
    Investigating the prognostic value of mTORC1 signaling in bladder cancer via bioinformatics evaluation.
    Sci Rep. 2023;13:22066.
    PubMed    
    Abstract available

  130. SLUSARCZYK A, Zapala P, Piecha T, Zapala L, et al
    Upper Urinary Tract Urothelial Cancer After Radical Cystectomy for Bladder Cancer: Survival Outcomes After Radical Nephroureterectomy.
    Ann Surg Oncol. 2023 Dec 12. doi: 10.1245/s10434-023-14710.
    PubMed    
    Abstract available

  131. ZOUEIN J, Boueri M, Kourie HR, Kattan J, et al
    Advanced bladder cancer management: history in the making.
    Future Oncol. 2023 Dec 12. doi: 10.2217/fon-2023-0908.
    PubMed    


  132. ZHENG X, Chen J, Deng M, Ning K, et al
    G3BP1 and SLU7 Jointly Promote Immune Evasion by Downregulating MHC-I via PI3K/Akt Activation in Bladder Cancer.
    Adv Sci (Weinh). 2023 Dec 12:e2305922. doi: 10.1002/advs.202305922.
    PubMed    
    Abstract available

  133. LEE S, Jue M, Lee K, Paulson B, et al
    Early-stage diagnosis of bladder cancer using surface-enhanced Raman spectroscopy combined with machine learning algorithms in a rat model.
    Biosens Bioelectron. 2023;246:115915.
    PubMed    
    Abstract available

  134. HEALTHCARE ENGINEERING JO
    Retracted: Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence.
    J Healthc Eng. 2023;2023:9801404.
    PubMed    
    Abstract available

  135. METHODS IN MEDICINE CAM
    Retracted: Effects of Nursing Care for the Treatment of Patients with Bladder Cancer: A Systematic Review and Meta-analysis.
    Comput Math Methods Med. 2023;2023:9876720.
    PubMed    
    Abstract available

  136. MEGHANI K, Frydenlund N, Yu Y, Choy B, et al
    A Spatial Comparison of Molecular Features Associated with Resistance to Pembrolizumab in BCG Unresponsive Bladder Cancer.
    medRxiv. 2023 Nov 29:2023.11.28.23299093. doi: 10.1101/2023.11.28.23299093.
    PubMed    
    Abstract available

  137. CHEN X, Zhang Z, Liao W, Zhao Y, et al
    Assessment tool based on fatty acid metabolic signatures for predicting the prognosis and treatment response in bladder cancer.
    Heliyon. 2023;9:e22768.
    PubMed    
    Abstract available

  138. FALLATAH M, Alkahtani AS, Alrumayyan M, Alotaibi MF, et al
    Trimodal therapy versus radical cystectomy for cT2N0M0 urothelial muscle-invasive bladder cancer: Single-center experience.
    Urol Ann. 2023;15:406-411.
    PubMed    
    Abstract available

  139. MARX AH, Nowicki DN, Carlson RB, Schultz KM, et al
    Bacille Calmette-Guerin preparation and intravesical administration to patients with bladder cancer: Risks to healthcare personnel and patients, and mitigation strategies.
    Infect Control Hosp Epidemiol. 2023 Dec 11:1-6. doi: 10.1017/ice.2023.
    PubMed    
    Abstract available

  140. LIU Y, Han YS, Wang JF, Pang ZQ, et al
    A new immune-related gene signature predicts the prognosis and immune escape of bladder cancer.
    Cancer Biomark. 2023 Nov 7. doi: 10.3233/CBM-230190.
    PubMed    
    Abstract available

  141. LIU Z, Du D, Zhang S
    Tumor-derived exosomal miR-1247-3p promotes angiogenesis in bladder cancer by targeting FOXO1.
    Cancer Biol Ther. 2024;25:2290033.
    PubMed    
    Abstract available

  142. EL-AGRODY E, Abol-Enein H, Mortada WI, Awadalla A, et al
    Does the Presence of Heavy Metals Influence the Gene Expression and Oxidative Stress in Bladder Cancer?
    Biol Trace Elem Res. 2023 Dec 11. doi: 10.1007/s12011-023-03950.
    PubMed    
    Abstract available

  143. CHEN X, Qin Z, Zhu X, Wang L, et al
    Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.
    Sci Rep. 2023;13:21816.
    PubMed    
    Abstract available

  144. MENG F, Zhang Z
    MicroRNA-152 specifically targets kinesin family member 14 to suppress the advancement of bladder cancer cells via PI3K/AKT pathway.
    Biochem Biophys Res Commun. 2023;692:149337.
    PubMed    
    Abstract available

  145. CARRASCO R, Ingelmo-Torres M, Trullas R, Roldan FL, et al
    Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer.
    Int J Mol Sci. 2023;24:16578.
    PubMed    
    Abstract available

  146. NEDJADI T, Ahmed ME, Ansari HR, Aouabdi S, et al
    Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis.
    Cancers (Basel). 2023;15:5704.
    PubMed    
    Abstract available

  147. KHOUYA A, Pottgen C, Hoffmann C, Ringbaek TP, et al
    Adaptation Time as a Determinant of the Dosimetric Effectiveness of Online Adaptive Radiotherapy for Bladder Cancer.
    Cancers (Basel). 2023;15:5629.
    PubMed    
    Abstract available

  148. RODRIGUEZ-IZQUIERDO M, Del Canizo CG, Rubio C, Reina IA, et al
    Immune Predictors of Response after Bacillus Calmette-Guerin Treatment in Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2023;15:5554.
    PubMed    
    Abstract available

  149. SANCHEZ-PELLICER P, Boix-Rodriguez C, Hernandez-Belmonte A, Encarnacion-Castellano C, et al
    Bladder Cancer and Probiotics: What Do We Know So Far?
    Cancers (Basel). 2023;15:5551.
    PubMed    
    Abstract available

  150. SEMENIUK-WOJTAS A, Modzelewska M, Poddebniak-Strama K, Kolaczynska S, et al
    CD4, CD20 and PD-L1 as Markers of Recurrence in Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2023;15:5529.
    PubMed    
    Abstract available

  151. OH CH
    Clinical efficacy and safety of percutaneous drainage for post-operative fluid collection in patients with bladder cancer undergoing radical cystectomy and urinary diversion.
    Medicine (Baltimore). 2023;102:e36488.
    PubMed    
    Abstract available

  152. LIU R, Yang J, Du Y, Yu X, et al
    A "One Arrow Three Eagle" Strategy to Improve CM-272 Primed Bladder Cancer Immunotherapy.
    Adv Mater. 2023 Dec 8:e2310522. doi: 10.1002/adma.202310522.
    PubMed    
    Abstract available

  153. LI Z, Li Y, Liu L, Zhang C, et al
    Multiple programmed cell death patterns and immune landscapes in bladder cancer: Evidence based on machine learning and multi-cohorts.
    Environ Toxicol. 2023 Dec 8. doi: 10.1002/tox.24066.
    PubMed    
    Abstract available

  154. CHEN H, Zhang Y, Chen X, Xu R, et al
    Hypoxia is correlated with the tumor immune microenvironment: Potential application of immunotherapy in bladder cancer.
    Cancer Med. 2023 Dec 8. doi: 10.1002/cam4.6617.
    PubMed    
    Abstract available

  155. ZHANG YH, Xie JJ, Wang JG, Wang Y, et al
    [Significance of TERT promoter mutation in differential diagnosis of non-invasive inverted urothelial lesions of bladder].
    Zhonghua Bing Li Xue Za Zhi. 2023;52:1216-1222.
    PubMed    
    Abstract available

  156. CHANG S, Bermoy ME, Chang SS, Scarpato KR, et al
    Enhancing the image quality of blue light cystoscopy through green-hue correction and fogginess removal.
    Sci Rep. 2023;13:21484.
    PubMed    
    Abstract available

  157. KWON AG, Brinzevich D, Borovik A, Bhalla R, et al
    Ileal conduit to small intestine fistula following extensive abdominopelvic resection and radiation for metastatic colon cancer.
    BMJ Case Rep. 2023;16:e254170.
    PubMed    
    Abstract available

  158. TAKAHASHI K, Urabe F, Suhara Y, Nakano J, et al
    Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective study.
    Jpn J Clin Oncol. 2023;53:1208-1214.
    PubMed    
    Abstract available

  159. AL-QUDIMAT AR, Singh K, Ojha LK, Moustafa DA, et al
    Comparing trimodal therapy with radical cystectomy in muscle-invasive bladder cancer: an updated meta-analysis.
    Front Surg. 2023;10:1276746.
    PubMed    
    Abstract available

  160. SHI X, Peng X, Chen Y, Shi Z, et al
    Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
    Front Immunol. 2023;14:1326509.
    PubMed    
    Abstract available

  161. MATSON M, Tien T, Yardy G, Allchorne P, et al
    The Use of Hospital Services by Patients With Muscle Invasive Bladder Cancer in the Last Year of Life: Identifying the Areas to Improve Care.
    Cureus. 2023;15:e49175.
    PubMed    
    Abstract available

  162. HU H, Lai S, Wang M, Tang X, et al
    Effect of subsequent bladder cancer on survival in upper tract urothelial carcinoma patients post-radical nephroureterectomy: a systematic review and meta-analysis.
    BMC Urol. 2023;23:212.
    PubMed    
    Abstract available

  163. CHEN Z, Liu Y, He A, Li J, et al
    Author Correction: Theophylline controllable RNAi-based genetic switches regulate expression of lncRNA TINCR and malignant phenotypes in bladder cancer cells.
    Sci Rep. 2023;13:22896.
    PubMed    


  164. LEBRET T, Bonastre J, Fraslin A, Neuzillet Y, et al
    Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life.
    BMJ Open. 2023;13:e075942.
    PubMed    
    Abstract available

  165. BAHLBURG H, Roghmann F
    [Overall survival and cancer-specific mortality in patients with very high-risk non-muscle-invasive bladder cancer (NMIBC) : Retrospective analysis of a US American single-center cohort].
    Urologie. 2023 Dec 21. doi: 10.1007/s00120-023-02252.
    PubMed    


  166. SONG Y, Xu T
    Letter to the editor for the article "Does the urinary microbiome profile change after treatment of bladder cancer?".
    World J Urol. 2023;42:2.
    PubMed    


  167. GALLIOLI A, Baboudjian M, Diana P, Moschini M, et al
    Perioperative and oncological outcomes of distal ureter management during nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and meta-analysis.
    Minerva Urol Nephrol. 2023;75:672-682.
    PubMed    
    Abstract available

  168. INTELLIGENCE AND NEUROSCIENCE
    Retracted: Comparative Analysis of the Efficacy of Transurethral Bipolar Plasma Needle Electrode and Ring Electrode in the Treatment of Non-Muscle-Invasive Bladder Cancer.
    Comput Intell Neurosci. 2023;2023:9824189.
    PubMed    
    Abstract available

  169. HIMURA R, Kawano S, Nagata Y, Kawai M, et al
    Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
    Chem Biol Interact. 2023 Dec 18:110840. doi: 10.1016/j.cbi.2023.110840.
    PubMed    
    Abstract available

  170. SARAY KILIC H, Pazar B, Ibrahimoglu O, Naldan ME, et al
    Quality of care perceived by patients during cystoscopy and affecting factors.
    Medicine (Baltimore). 2023;102:e36314.
    PubMed    
    Abstract available

  171. XU Y, Li Q, Lin H
    Bioinformatics analysis of CMTM family in pan-cancer and preliminary exploration of CMTM6 in bladder cancer.
    Cell Signal. 2023 Dec 17:111012. doi: 10.1016/j.cellsig.2023.111012.
    PubMed    
    Abstract available

  172. DIAZ ACEDO R, Galvan Banqueri M, Artacho Criado S, Fernandez Parra EM, et al
    Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer.
    Int J Clin Pharm. 2023 Dec 19. doi: 10.1007/s11096-023-01667.
    PubMed    
    Abstract available

  173. MATSUSHITA Y, Miyake M, Nishimura N, Nishimoto K, et al
    Comparative assessment of disease recurrence after transurethral resection of non-muscle-invasive bladder cancer with and without a photodynamic diagnosis using 5-aminolevulinic acid: a propensity score-matching analysis.
    Int J Clin Oncol. 2023 Dec 19. doi: 10.1007/s10147-023-02447.
    PubMed    
    Abstract available

  174. PIERINI A, Criscuolo MC, Caccamo R, Bottero E, et al
    A case series of urinary bladder rhabdomyosarcoma in seven dogs.
    Open Vet J. 2023;13:1498-1503.
    PubMed    
    Abstract available

  175. PENG M, Chu X, Peng Y, Li D, et al
    Targeted therapies in bladder cancer: signaling pathways, applications, and challenges.
    MedComm (2020). 2023;4:e455.
    PubMed    
    Abstract available

  176. PENG J, Weng Z, Zhang C, Zhou G, et al
    Analysis of prognostic factors in patients diagnosed with bladder cancer complicated by hemorrhage treated by drug-eluting bead embolization.
    Transl Androl Urol. 2023;12:1697-1707.
    PubMed    
    Abstract available

  177. WANG KR, Simhal RK, Dinatale GG, Li L, et al
    Recurring cystitis cystica and cystitis glandularis masquerading as urothelial carcinoma.
    Can J Urol. 2023;30:11752-11755.
    PubMed    
    Abstract available

  178. QIAN Z, Ye J, Friedlander DF, Koelker M, et al
    Impact of COVID-19 pandemic on ambulatory urologic oncology surgeries.
    Can J Urol. 2023;30:11714-11723.
    PubMed    
    Abstract available

  179. OGURA R, Ito S, Ueda T, Gabata Y, et al
    Author Correction: Screening for a practical method to monitor the status of patients with metastatic bladder cancer at the circulating cell-gene level.
    Sci Rep. 2023;13:22350.
    PubMed    


  180. DERRE L, Lucca I, Cesson V, Bohner P, et al
    Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.
    J Immunother Cancer. 2023;11:e008020.
    PubMed    
    Abstract available

  181. WONG C
    The cancer physician who helped to deliver a life-extending treatment.
    Nature. 2023;624:508.
    PubMed    


  182. OBI H, Nagao K, Aoki M, Nagura S, et al
    [Thoracic Endovascular Aortic Repair for Mycotic Thoracic Aortic Aneurysm After BCG Intravesical Therapy].
    Kyobu Geka. 2023;76:1083-1089.
    PubMed    
    Abstract available

  183. NAVRIYA SC, Singh V, Choudhary GR, Tripathi S, et al
    Postradical cystectomy delayed urethral recurrence: a rare presentation posing diagnostic dilemma.
    BMJ Case Rep. 2023;16:e256700.
    PubMed    
    Abstract available

  184. LIN S, Chai Y, Zheng X, Xu X, et al
    The role of HIF in angiogenesis, lymphangiogenesis, and tumor microenvironment in urological cancers.
    Mol Biol Rep. 2023;51:14.
    PubMed    
    Abstract available

  185. JAIN K, Datta C, Sengupta M, Pal DK, et al
    Quest to develop a standard screening method for urothelial carcinoma using liquid-based cytology (The Paris System) and CK20.
    Indian J Pathol Microbiol. 2023;66:720-726.
    PubMed    
    Abstract available

  186. BAI Y, Wu X, Weng M, Han Q, et al
    The expression of SP263 in muscle invasive bladder carcinoma and its relationship with clinicopathological features.
    Indian J Pathol Microbiol. 2023;66:702-707.
    PubMed    
    Abstract available

  187. YUE R, Dutta A
    Koopman-based Impulsive Model Predictive Control of BCG Immunotherapy.
    Annu Int Conf IEEE Eng Med Biol Soc. 2023;2023:1-4.
    PubMed    
    Abstract available

  188. SUN J, Zhang Y, Yang L, Zhou L, et al
    [High expression of long noncoding RNA UCA1 promotes invasion, migration and epithelial-mesenchymal transition of trophoblasts in vitro].
    Nan Fang Yi Ke Da Xue Xue Bao. 2023;43:1984-1988.
    PubMed    
    Abstract available

  189. LESLIE M
    Tumor-killing viruses score rare success in late-stage trial.
    Science. 2023;382:1101-1102.
    PubMed    
    Abstract available

  190. ELLIS JL, Dalimov Z, Chew L, Quek ML, et al
    Preoperative optimization of the radical cystectomy patient: Current state and future directions.
    J Surg Oncol. 2024;129:138-144.
    PubMed    
    Abstract available

  191. WU P, Liu J, Wang X, Lai S, et al
    Development and validation of a nomogram based on geriatric nutritional risk index for predicting prognosis and postoperative complications in surgical patients with upper urinary tract urothelial carcinoma.
    J Cancer Res Clin Oncol. 2023;149:18185-18200.
    PubMed    
    Abstract available

  192. VARVIL MS, Clark SL, Bailey TW, Ramos-Vara JA, et al
    Canine urothelial carcinoma: a pilot study of microRNA detection in formalin-fixed, paraffin-embedded tissue samples and in normal urine.
    J Vet Diagn Invest. 2024;36:70-77.
    PubMed    
    Abstract available

  193. LI J, Huang X, Wang L, Wang X, et al
    Role of Contrast-Enhanced Ultrasound With the Enhancement Pattern and Qualitative Analysis for Differentiating Hypovascular Solid Renal Lesions.
    Ultrasound Med Biol. 2024;50:295-303.
    PubMed    
    Abstract available

  194. HAN F, Wu Z, Chen J, Liu M, et al
    The efficacy and safety of chemotherapy with or without anti-PD-1 for the first-line treatment of advanced urothelial carcinoma.
    Cancer Med. 2023;12:21129-21137.
    PubMed    
    Abstract available

  195. WEISS K, Gessner KH, Demzik A, Moreton E, et al
    Molecular characterization of plasmacytoid urothelial carcinoma and the impact on treatment implications.
    Cancer Treat Res Commun. 2023;37:100779.
    PubMed    
    Abstract available

  196. CAI TN, Lu JL, Chen Z, Liu ZH, et al
    Optimal interval timing between transurethral resection of bladder tumors and Bacillus Calmette-Guerin perfusion.
    Cancer Med. 2023;12:21279-21286.
    PubMed    
    Abstract available

  197. NADAL R, Valderrama BP, Bellmunt J
    Progress in systemic therapy for advanced-stage urothelial carcinoma.
    Nat Rev Clin Oncol. 2024;21:8-27.
    PubMed    
    Abstract available

  198. XU J, Zhang H, Zhang L, Chu X, et al
    Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study.
    Cancer Med. 2023;12:21159-21171.
    PubMed    
    Abstract available

  199. SANTONI M, Massari F, Takeshita H, Tapia JC, et al
    Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.
    Clin Exp Med. 2023;23:5413-5422.
    PubMed    
    Abstract available


  200. UC Trials Get Standing Ovation.
    Cancer Discov. 2023;13:2496.
    PubMed    
    Abstract available

  201. TYSON MD, Abouassaly R, Durant A, Smith AB, et al
    Budgetary Impact of Including the Urinary Genomic Marker Cxbladder Detect in the Evaluation of Microhematuria Patients.
    Urol Pract. 2024;11:54-60.
    PubMed    
    Abstract available

  202. ZHANG WJ, Huang XY, Lin B, Zheng WC, et al
    The effect of body mass index on quality of life in modified single stoma cutaneous ureterostomy or ileal conduit after radical cystectomy.
    Cancer Med. 2023;12:20930-20939.
    PubMed    
    Abstract available

  203. OHTSU A, Arai S, Fujizuka Y, Miyazawa Y, et al
    Predictive models of long-term survival outcomes following radical cystectomy.
    Cancer Med. 2023;12:21118-21128.
    PubMed    
    Abstract available

  204. GHELANI GH, Zerdan MB, Jacob J, Spiess PE, et al
    HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
    Urol Oncol. 2023;41:486.
    PubMed    
    Abstract available

  205. HOU Y, Du W, Wu Q, Chai X, et al
    PDGFRA exhibits potential as an indicator of angiogenesis within the tumor microenvironment and is up-regulated in BLCA.
    Microvasc Res. 2024;151:104614.
    PubMed    
    Abstract available

  206. SOLTANTABAR P, Alhadab A, Hibma J, Roychoudhury S, et al
    Case-control matching-guided exposure-efficacy relationship for avelumab in patients with urothelial carcinoma.
    CPT Pharmacometrics Syst Pharmacol. 2023;12:2001-2012.
    PubMed    
    Abstract available

  207. LIU Y, Wang J
    Inflammatory myofibroblastic tumors of the bladder in a 20-year-old female.
    Asian J Surg. 2023;46:5567-5568.
    PubMed    


  208. KOMURA K, Tokushige S, Ishida M, Hirosuna K, et al
    Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab.
    Cancer Sci. 2023;114:4622-4631.
    PubMed    
    Abstract available

  209. JIANG Y, Tang Y, Zhang Q, Liang S, et al
    Development of a nomogram for predicting overall survival in patients with urinary bladder carcinoma in situ based on SEER database analysis.
    Asian J Surg. 2023;46:6015-6017.
    PubMed    


  210. XIAO P, Liu J, Sun W, Wang J, et al
    Large cell neuroendocrine carcinoma of the urinary bladder: A case report and literature review.
    Asian J Surg. 2023;46:6049-6050.
    PubMed    


  211. MAI Z, Yuan R, Wu L, Yan W, et al
    Genetic testing and innovative surgery for familial urinary bladder paraganglioma: Report of two cases and literature review.
    Asian J Surg. 2023;46:6053-6055.
    PubMed    


  212. HE B, Chen Y, Hui Z
    Primary pure bladder large cell neuroendocrine carcinoma: A case report.
    Asian J Surg. 2023;46:5454-5455.
    PubMed    


  213. WANG H, Fei J, Yu X
    Synchronous renal pelvic urothelial carcinoma and oncocytoma: A case report.
    Asian J Surg. 2023;46:5952-5953.
    PubMed    


  214. CIVRIZ AH, Teke K, Akdas EM, Dillioglugil O, et al
    The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment.
    Urol Oncol. 2023;41:486.
    PubMed    
    Abstract available

  215. CANNON E, Ntala C, Joss N, Rahilly M, et al
    High grade urothelial carcinoma in kidney transplant patients with a history of BK viremia - Just a coincidence?
    Clin Transplant. 2023 Aug 31:e15113. doi: 10.1111/ctr.15113.
    PubMed    
    Abstract available

  216. YU CC, Chang CH, Fang JK, Huang SK, et al
    Impact of pathological response on oncological outcomes in patients with upper tract urothelial cancer receiving neo-adjuvant chemotherapy.
    J Formos Med Assoc. 2023;122:1274-1281.
    PubMed    
    Abstract available

  217. UCCELLO M, Adeleke S, Moschetta M, Ghose A, et al
    Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence.
    Ann Palliat Med. 2023;12:1345-1354.
    PubMed    
    Abstract available

  218. SANDA GE, Shabto JM, Goyal S, Liu Y, et al
    Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Oncologist. 2023;28:1072-1078.
    PubMed    
    Abstract available

  219. LINEHAN J, Gottlieb J, Woldu SL, Labbate C, et al
    Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes.
    Eur Urol Focus. 2023;9:1052-1058.
    PubMed    
    Abstract available

  220. KATSIMPERIS S, Tzelves L, Tandogdu Z, Ta A, et al
    Complications After Radical Cystectomy: A Systematic Review and Meta-analysis of Randomized Controlled Trials with a Meta-regression Analysis.
    Eur Urol Focus. 2023;9:920-929.
    PubMed    
    Abstract available

  221. SAKURAI Y, Furuto Y, Saito T, Namikawa A, et al
    Disseminated Bacillus Calmette-Guerin Infection with Rhabdomyolysis, Acute Kidney Injury, and Interstitial Pneumonia after Bacillus Calmette-Guerin Intravesical Instillation Therapy.
    Intern Med. 2023;62:3707-3712.
    PubMed    
    Abstract available

  222. LAUKHTINA E, Quhal F, von Deimling M, Kawada T, et al
    For Which Patients Should Bladder Preservation Be Considered After a Complete Response to Neoadjuvant Chemotherapy.
    Eur Urol Focus. 2023;9:900-902.
    PubMed    
    Abstract available

  223. JAHANGIRIAN E, Zargan J, Rabbani H, Zamani J, et al
    Investigating the inhibitory and penetrating properties of three novel anticancer and antimicrobial scorpion peptides via molecular docking and molecular dynamic simulation.
    J Biomol Struct Dyn. 2023;41:15354-15385.
    PubMed    
    Abstract available

  224. CHEN X, Chen H, Lin R, Li Y, et al
    Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma.
    J Clin Pathol. 2023;77:61-67.
    PubMed    
    Abstract available

  225. KIM HJ, Sim JY, Kim MB, Chang SW, et al
    Unusual Cervical Lymph Node Metastasis of Papillary Urothelial Carcinoma.
    Ear Nose Throat J. 2024;103:NP4-NP6.
    PubMed    
    Abstract available

  226. WANG Z, Kwan ML, Haque R, Pratt R, et al
    Environmental and Occupational Exposures and Prognosis in Patients with Non-Muscle Invasive Bladder Cancer in the Be-Well Study.
    Am J Epidemiol. 2023 Dec 5:kwad236. doi: 10.1093.
    PubMed    
    Abstract available

  227. FURUBAYASHI N, Minato A, Tomoda T, Hori Y, et al
    Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study.
    Anticancer Res. 2023;43:5689-5698.
    PubMed    
    Abstract available

  228. ROGERS Z, Glaser A, Catto JWF, Bottomley S, et al
    Quality of life after a diagnosis of Bladder Cancer: Longitudinal survey over the first year.
    BJU Int. 2023 Nov 29. doi: 10.1111/bju.16242.
    PubMed    
    Abstract available

  229. MASTROIANNI R, Tuderti G, Ferriero M, Anceschi U, et al
    Open versus robot-assisted radical cystectomy: pentafecta and trifecta achievement comparison from a randomised controlled trial.
    BJU Int. 2023;132:671-677.
    PubMed    
    Abstract available

  230. HACK J, Douglas J, Makaroff L, Costin M, et al
    Patient Experience of Surveillance Following Radical Treatment for Muscle-Invasive Bladder Cancer.
    BJU Int. 2023 Dec 14. doi: 10.1111/bju.16261.
    PubMed    


  231. VITUG C, Lajkosz K, Chavarriaga J, Llano A, et al
    Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancer.
    BJU Int. 2023 Dec 17. doi: 10.1111/bju.16269.
    PubMed    
    Abstract available

  232. VIERGEVER BJ, Raats DAE, Geurts V, Mullenders J, et al
    Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation.
    Br J Cancer. 2023 Dec 15. doi: 10.1038/s41416-023-02494.
    PubMed    
    Abstract available

  233. LINDSKROG SV, Birkenkamp-Demtroder K, Nordentoft I, Laliotis G, et al
    Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up.
    Clin Cancer Res. 2023;29:4797-4807.
    PubMed    
    Abstract available

  234. GELIKMAN DG, Rais-Bahrami S, Pinto PA, Turkbey B, et al
    AI-powered radiomics: revolutionizing detection of urologic malignancies.
    Curr Opin Urol. 2024;34:1-7.
    PubMed    
    Abstract available

  235. IKEDA A, Nosato H
    Overview of current applications and trends in artificial intelligence for cystoscopy and transurethral resection of bladder tumours.
    Curr Opin Urol. 2024;34:27-31.
    PubMed    
    Abstract available

  236. BECKABIR W, Wobker SE, Damrauer JS, Midkiff B, et al
    Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Dec 12:S0302-2838(23)03261-X. doi: 10.1016/j.eururo.2023.
    PubMed    
    Abstract available

  237. XIE Q, Shen D
    Re: Bhavan P. Rai, Jose Luis Dominguez Escrig, Luis Vale, et al. Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria. Eur Urol 2022;82:182-92.
    Eur Urol. 2024;85:e17-e18.
    PubMed    


  238. PRASAD RAI B, Violette PD, Imran Omar M
    Reply to Qingpeng Xie and Dianqiu Shen's Letter to the Editor re: Bhavan P. Rai, Jose Luis Dominguez Escrig, Luis Vale, et al. Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with H
    Eur Urol. 2024;85:e15-e16.
    PubMed    


  239. HASHIMOTO T
    Editorial Comment to Enfortumab vedotin versus platinum rechallenge in post-platinum post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
    Int J Urol. 2023;30:1186-1187.
    PubMed    


  240. TAGUCHI S, Kawai T, Ambe Y, Kishitani K, et al
    Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
    Int J Urol. 2023;30:1180-1186.
    PubMed    
    Abstract available

  241. KATO M, Uchida J
    Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review.
    Int J Urol. 2023;30:1068-1077.
    PubMed    
    Abstract available

  242. GOTO Y
    Editorial Comment on Urinary markers for bladder cancer diagnosis: A review of current status and future challenges.
    Int J Urol. 2023 Dec 10. doi: 10.1111/iju.15360.
    PubMed    


  243. ARAI S
    Editorial Comment on Epigenetic alterations in urothelial bladder cancer associated with disease outcomes.
    Int J Urol. 2023 Dec 10. doi: 10.1111/iju.15361.
    PubMed    


  244. CATHOMAS R, Rothschild SI, Hayoz S, Bubendorf L, et al
    Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
    J Clin Oncol. 2023;41:5131-5139.
    PubMed    
    Abstract available

  245. HE W, Zeng S, Xu C
    Controversy Surrounding Bladder-Sparing Radical Dose Radiotherapy as an Alternative to Radical Cystectomy for Clinically Node-Positive Nonmetastatic Bladder Cancer.
    J Clin Oncol. 2023 Dec 5:JCO2301920. doi: 10.1200/JCO.23.01920.
    PubMed    


  246. YU J, Li M, Ju L, Zhou F, et al
    TRAIP suppresses bladder cancer progression by catalyzing K48-linked polyubiquitination of MYC.
    Oncogene. 2023 Dec 20. doi: 10.1038/s41388-023-02922.
    PubMed    
    Abstract available

  247. YE G, Tu L, Li Z, Li X, et al
    SYNPO2 promotes the development of BLCA by upregulating the infiltration of resting mast cells and increasing the resistance to immunotherapy.
    Oncol Rep. 2024;51:14.
    PubMed    
    Abstract available

  248. CHEN F, Chen X, Yang D, Che X, et al
    [Retracted] Isoquercitrin inhibits bladder cancer progression in vitro and in vivo by regulating the PI3K/Akt and PKC signaling pathways.
    Oncol Rep. 2024;51:25.
    PubMed    
    Abstract available

  249. GALLON J, LeMaoult J, Verine J, Dumont C, et al
    [Profile and immune environment of upper tract urothelial carcinoma].
    Prog Urol. 2023;33.
    PubMed    
    Abstract available

  250. BRUNEAUX E, Iborra F, Trouche-Sabatier SG, Foucan AS, et al
    [Bladder tumors in the Herault department: Results of the Herault tumor registry registration from1987 to 2019].
    Prog Urol. 2023;33.
    PubMed    
    Abstract available

  251. GUO Y, Li C, Zhang S, Zhu G, et al
    U-Net-Based Assistive Identification of Bladder Cancer: A Promising Approach for Improved Diagnosisc.
    Urol Int. 2023 Dec 11. doi: 10.1159/000535652.
    PubMed    
    Abstract available

  252. WANG C, Yu H, Fu W, Chen G, et al
    Transurethral Hem-o-lok Clip Ligation of the Distal Ureter in Retroperitoneal Laparoscopic Radical Nephroureterectomy.
    Urol Int. 2023;107.
    PubMed    
    Abstract available

  253. TULONE G, Pavan N, Giannone S, Abrate A, et al
    Double-Layered Hand-Sewn versus Stapled Intestinal Anastomosis in Patients Who Underwent Ileal Urinary Diversion in Radical Cystectomy: A Comparative and Cost Effective Study.
    Urol Int. 2023;107.
    PubMed    
    Abstract available

  254. GUL ZG, Wu S, Raver M, Vasan R, et al
    A Multipronged Intervention to Reduce Readmissions and Readmission Intensity After Radical Cystectomy.
    Urology. 2023;182:155-160.
    PubMed    
    Abstract available

  255. ZHU A, Srivastava A
    Editorial Comment: Does Alexis Wound Protector/Retractor Reduce the Risk of Surgical Site Infections After Open Radical Cystectomy for Bladder Cancer? Results From a Single Center, Comparative Study.
    Urology. 2023 Dec 14:S0090-4295(23)00958-5. doi: 10.1016/j.urology.2023.
    PubMed    


  256. LEONARDO K, Mirza H, Seno DH, Purnomo N, et al
    Transperitoneal vs extraperitoneal radical cystectomy: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0294809.
    PubMed    
    Abstract available

  257. WANG E, Hagberg O, Malmstrom PU
    The association between BCG treatment in patients with bladder cancer and subsequent risk of developing Alzheimer and other dementia.-A Swedish nationwide cohort study from 1997 to 2019.
    PLoS One. 2023;18:e0292174.
    PubMed    
    Abstract available

  258. ZHAO Z, Aoi Y, Philips CN, Meghani KA, et al
    Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment.
    Proc Natl Acad Sci U S A. 2023;120:e2310063120.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.


;